Product Information
UBRELVY 100 MG TABLET is a brand product labeled by Allergan, Inc., priced at $109.1070 per EA under NDC 00023650116. Its NADAC has been published 223 times since Jun 29, 2022.
FDA first approved this application on Dec 23, 2019.
Strength
100 mg/1
Manufacturer
Allergan, Inc.NDC
00023650116
Classification
Brand
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
UBROGEPANTApproval Type
New Drug (NDA)
FDA Application
NDA211765FDA Approved
12/23/2019
On Market Since
12/23/2019
Pharmacological Classes
Price Statistics
The NADAC for UBRELVY 100 MG TABLET has been published 223 times since Jun 29, 2022, and over the history we have for it it has risen 21.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $109.1070 per EA |
|---|---|
| All-time high | $109.1882 (May 13, 2026) |
| All-time low | $90.0749 (Jun 29, 2022) |
| 52-week high | $109.1882 |
| 52-week low | $103.9496 |
| Median price | $99.2148 |
| Average price | $99.8044 |
| Largest weekly change | +5.0% (Jan 10, 2024) |
| Weeks tracked | 223 |
| Tracking since | Jun 29, 2022 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Allergan, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
ubrogepant market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Calcitonin Gene-related Peptide Receptor Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of UBRELVY 100 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for UBRELVY 100 MG TABLET, manufactured by Allergan, Inc., is $109.1070 per EA (NDC 00023650116), effective Sep 30, 2026.
How has the price of UBRELVY 100 MG TABLET changed over time?
Over the history we have for it, the NADAC for UBRELVY 100 MG TABLET has risen 21.1%. It has been tracked across 223 weekly CMS publications since Jun 29, 2022.
What are the highest and lowest recorded NADAC prices for UBRELVY 100 MG TABLET?
Since Jun 29, 2022, the NADAC for UBRELVY 100 MG TABLET has ranged from a low of $90.0749 (Jun 29, 2022) to a high of $109.1882 (May 13, 2026), with a median of $99.2148 per EA.
Are there cheaper alternatives to UBRELVY 100 MG TABLET?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as UBRELVY 100 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures UBRELVY 100 MG TABLET?
UBRELVY 100 MG TABLET (NDC 00023650116) is labeled by Allergan, Inc., and CMS classifies it as a brand product.